Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Long-Term Debt Repayments (2021 - 2023)

Historic Long-Term Debt Repayments for InMed Pharmaceuticals (INM) over the last 3 years, with Q4 2023 value amounting to $94400.0.

  • InMed Pharmaceuticals' Long-Term Debt Repayments fell 1276.14% to $94400.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $410572.0, marking a year-over-year increase of 2879.8%. This contributed to the annual value of $426575.0 for FY2023, which is 2477.99% up from last year.
  • As of Q4 2023, InMed Pharmaceuticals' Long-Term Debt Repayments stood at $94400.0, which was down 1276.14% from $98709.0 recorded in Q3 2023.
  • InMed Pharmaceuticals' Long-Term Debt Repayments' 5-year high stood at $214791.0 during Q4 2021, with a 5-year trough of $17411.0 in Q3 2021.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $99806.0 (2022), whereas its average is $96154.6.
  • Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Long-Term Debt Repayments was 47953.59% (2022), while the steepest drop was 4962.13% (2022).
  • Quarter analysis of 3 years shows InMed Pharmaceuticals' Long-Term Debt Repayments stood at $214791.0 in 2021, then crashed by 49.62% to $108209.0 in 2022, then fell by 12.76% to $94400.0 in 2023.
  • Its Long-Term Debt Repayments stands at $94400.0 for Q4 2023, versus $98709.0 for Q3 2023 and $109085.0 for Q2 2023.